140 related articles for article (PubMed ID: 19938885)
1. Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors.
Soares J
Clin Drug Investig; 2009; 29 Suppl 2():26-8. PubMed ID: 19938885
[TBL] [Abstract][Full Text] [Related]
2. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
[TBL] [Abstract][Full Text] [Related]
3. Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
Yuan Y; Hunt RH
Curr Pharm Des; 2007; 13(22):2237-47. PubMed ID: 17691997
[TBL] [Abstract][Full Text] [Related]
4. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
[TBL] [Abstract][Full Text] [Related]
5. Recurrent duodenal ulcer due to nonsteroidal anti-inflammatories following the suspension of antiulcer medication.
Silva AP
Clin Drug Investig; 2009; 29 Suppl 2():23-5. PubMed ID: 19938884
[TBL] [Abstract][Full Text] [Related]
6. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
El Miedany Y; Youssef S; Ahmed I; El Gaafary M
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
[TBL] [Abstract][Full Text] [Related]
7. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Goldstein JL; Huang B; Amer F; Christopoulos NG
Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
[TBL] [Abstract][Full Text] [Related]
8. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study.
Bianchi Porro G; Lazzaroni M; Imbesi V; Montrone F; Santagada T
Dig Liver Dis; 2000 Apr; 32(3):201-8. PubMed ID: 10975769
[TBL] [Abstract][Full Text] [Related]
10. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
[TBL] [Abstract][Full Text] [Related]
11. Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy.
Moro MG; Sanchez PK; Gevert MV; Baller EM; Tostes AF; Lupepsa AC; Baglie S; Franco GC
Braz Oral Res; 2016 Nov; 30(1):e127. PubMed ID: 27901208
[TBL] [Abstract][Full Text] [Related]
12. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population.
García Rodríguez LA; Barreales Tolosa L
Gastroenterology; 2007 Feb; 132(2):498-506. PubMed ID: 17258728
[TBL] [Abstract][Full Text] [Related]
13. Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs.
Muratore L; Ventura M; Calogiuri G; Calcagnile F; Quarta E; Muratore M; Ferrannini A
Ann Allergy Asthma Immunol; 2007 Feb; 98(2):168-71. PubMed ID: 17304885
[TBL] [Abstract][Full Text] [Related]
14. Selective COX-2 inhibitors: a promise unfulfilled?
Henry D; McGettigan P
Gastroenterology; 2007 Feb; 132(2):790-4. PubMed ID: 17261306
[No Abstract] [Full Text] [Related]
15. A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs.
Nakashima S; Arai S; Mizuno Y; Yoshino K; Ando S; Nakamura Y; Sugawara K; Koike M; Saito E; Naito M; Nakao M; Ito H; Hamaoka K; Rai F; Asakura Y; Akamatu M; Fujimori K; Inao M; Imai Y; Ota S; Fujiwara K; Shiibashi M
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():60-6. PubMed ID: 15943849
[TBL] [Abstract][Full Text] [Related]
16. Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Taha AS; McCloskey C; McSkimming P; McConnachie A
Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):469-476. PubMed ID: 29754836
[TBL] [Abstract][Full Text] [Related]
17. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
Hunt RH; Harper S; Callegari P; Yu C; Quan H; Evans J; James C; Bowen B; Rashid F
Aliment Pharmacol Ther; 2003 Jan; 17(2):201-10. PubMed ID: 12534404
[TBL] [Abstract][Full Text] [Related]
18. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats.
Fracon RN; Teófilo JM; Moris IC; Lamano T
J Appl Oral Sci; 2010 Dec; 18(6):630-4. PubMed ID: 21308296
[TBL] [Abstract][Full Text] [Related]
19. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs.
Doña I; Blanca-López N; Jagemann LR; Torres MJ; Rondón C; Campo P; Gómez AI; Fernández J; Laguna JJ; Rosado A; Blanca M; Canto G
Allergy; 2011 Nov; 66(11):1428-33. PubMed ID: 21834936
[TBL] [Abstract][Full Text] [Related]
20. Mucosal exfoliation as a selective reaction to etoricoxib.
Patanè M; Isola S; Gangemi S; Minciullo PL
J Clin Pharm Ther; 2016 Dec; 41(6):722-724. PubMed ID: 27576781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
